Characterization Of Glycoprotein Iib/Iiia-Specific Alloantibodies Induced By Cross-Strain Platelet Immunization In Mice

Background We previously described a mouse model in which platelet immunization between selected strains leads to production of alloantibodies and severe autoimmune thrombocytopenia and mimics the human condition posttransfusion purpura (PTP). This report describes studies defining epitopes recognized by these alloantibodies.Study Design Hybridomas were produced from spleen cells of immunized mice. Glycoprotein (GP) targets of resulting monoclonal antibodies were characterized by immunoprecipitation using platelets from the immunizing strains. Antigens defined by single amino acid (AA) polymorphisms recognized by monoclonal antibodies were identified by selectively mutagenizing target glycoproteins expressed in Chinese hamster ovary cells and observing the effects on antibody binding.Results Three monoclonal antibodies (417.1, 417.3, 425.1) were produced that recognized GPIIb on immunizing platelets. Monoclonal antibodies 417.1 and 417.3 both required G111 and 425.1 required V37, located on the beta propeller domain of GPIIb, for binding to platelets from the immunizing strains C57 and PWK, respectively. Injection of 417.3 and 425.1 into mice caused platelet destruction only in mice with GPIIb containing the targeted AAs.Conclusions Findings made provide evidence that alloantibodies produced by mice experiencing autoimmune thrombocytopenia in a mouse model of PTP are specific for single AA polymorphisms that differ in GPIIb/IIIa integrin of the immunizing and immunized strains and are closely analogous therefore closely resemble the potent alloantibodies found in patients with PTP. The observations indicate show that naturally occurring single AA differences in GPIIb/IIIa integrin of various mouse strains are highly immunogenic in the mouse strains studied and capable of inducing readily induce antibodies comparable to human platelet antigen-specific antibodies found in transfused and pregnant humans. Patients.